Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV

Treatment with tenofovir alafenamide fumarate (TAF) is associated with body weight gain. However, little or no information is available on this issue in Asian populations. This single-center retrospective study included Japanese people living with HIV (PLWH) who satisfied the following criteria; 1)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2023-02, Vol.29 (2), p.171-178
Main Authors: Sekiya, Ryoko, Muramatsu, Takashi, Ichiki, Akito, Chikasawa, Yushi, Bingo, Masato, Yotsumoto, Mihoko, Hagiwara, Takeshi, Amano, Kagehiro, Kinai, Ei
Format: Article
Language:English
Subjects:
Japanese
Lipid change
Tenofovir alafenamide
Weight gain
Young age
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment with tenofovir alafenamide fumarate (TAF) is associated with body weight gain. However, little or no information is available on this issue in Asian populations. This single-center retrospective study included Japanese people living with HIV (PLWH) who satisfied the following criteria; 1) switching from TDF to TAF after HIV-suppression, 2) follow-up for ≥2 years while on TDF and TAF, and 3) no switching of the third antiretroviral agent. Changes in annual body weight and lipid profiles were compared between the TDF and TAF periods. Of 328 patients, dolutegravir (DTG) was used in 118 PLWH. Overall, no significant difference in weight gain was observed between TDF and TAF (0.76 vs. 0.9 kg/year, p = 0.331). In TAF-period, younger (
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2022.10.014